NASDAQ:XENT

Intersect ENT (XENT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$28.24
$28.24
50-Day Range
$28.24
$28.24
52-Week Range
$15.92
$28.25
Volume
14,512 shs
Average Volume
351,526 shs
Market Capitalization
$954.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
XENT stock logo

About Intersect ENT Stock (NASDAQ:XENT)

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

XENT Stock News Headlines

XENT Historical Data
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
DexCom (DXCM) Misses Q1 Earnings Estimates
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
See More Headlines
Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:XENT
Employees
433
Year Founded
N/A

Profitability

Net Income
$-159,630,000.00
Net Margins
-161.94%
Pretax Margin
-163.16%

Debt

Sales & Book Value

Annual Sales
$106.75 million
Book Value
($2.06) per share

Miscellaneous

Free Float
33,104,000
Market Cap
$954.91 million
Optionable
Optionable
Beta
1.45
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Thomas A. West (Age 58)
    Pres, CEO & Director
    Comp: $908.97k
  • Mr. Richard A. Meier (Age 62)
    Exec. VP & CFO
    Comp: $621.76k
  • Mr. Patrick A. Broderick (Age 63)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $138.46k
  • Ms. Reyna M. Fernandez
    Chief Human Resource Officer
  • Mr. Drake R. Parker (Age 58)
    Advisor of Strategic Initiatives

XENT Stock Analysis - Frequently Asked Questions

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its quarterly earnings data on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The medical equipment provider earned $24.40 million during the quarter, compared to analysts' expectations of $29.63 million. Intersect ENT had a negative net margin of 161.94% and a negative trailing twelve-month return on equity of 709.52%.

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT Chief Executive Officer Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among the company's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intersect ENT own?
This page (NASDAQ:XENT) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners